DK1408106T3 - Cancer immunterapi - Google Patents
Cancer immunterapiInfo
- Publication number
- DK1408106T3 DK1408106T3 DK02022787T DK02022787T DK1408106T3 DK 1408106 T3 DK1408106 T3 DK 1408106T3 DK 02022787 T DK02022787 T DK 02022787T DK 02022787 T DK02022787 T DK 02022787T DK 1408106 T3 DK1408106 T3 DK 1408106T3
- Authority
- DK
- Denmark
- Prior art keywords
- lymphocytes
- sentinel
- dukes
- nodes
- proliferation
- Prior art date
Links
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 15
- 206010028980 Neoplasm Diseases 0.000 abstract 8
- 230000035755 proliferation Effects 0.000 abstract 7
- 210000001165 lymph node Anatomy 0.000 abstract 5
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 abstract 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 abstract 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 abstract 3
- 206010027476 Metastases Diseases 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 239000000284 extract Substances 0.000 abstract 3
- 230000001394 metastastic effect Effects 0.000 abstract 3
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 3
- 210000005259 peripheral blood Anatomy 0.000 abstract 3
- 239000011886 peripheral blood Substances 0.000 abstract 3
- 210000005005 sentinel lymph node Anatomy 0.000 abstract 3
- 108010062580 Concanavalin A Proteins 0.000 abstract 2
- 102000015696 Interleukins Human genes 0.000 abstract 2
- 108010063738 Interleukins Proteins 0.000 abstract 2
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 239000001045 blue dye Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 208000029742 colonic neoplasm Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000684 flow cytometry Methods 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 230000000638 stimulation Effects 0.000 abstract 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 abstract 1
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 abstract 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010034650 Peritoneal adhesions Diseases 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001516 cell proliferation assay Methods 0.000 abstract 1
- 239000006285 cell suspension Substances 0.000 abstract 1
- 201000011024 colonic benign neoplasm Diseases 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000002224 dissection Methods 0.000 abstract 1
- 231100000673 dose–response relationship Toxicity 0.000 abstract 1
- 239000000975 dye Substances 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000007689 inspection Methods 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000009696 proliferative response Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0651—Lymph nodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02022787A EP1408106B1 (en) | 2002-10-11 | 2002-10-11 | Cancer immuno-therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1408106T3 true DK1408106T3 (da) | 2007-06-11 |
Family
ID=32010966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02022787T DK1408106T3 (da) | 2002-10-11 | 2002-10-11 | Cancer immunterapi |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8709404B2 (da) |
| EP (2) | EP1808200A3 (da) |
| JP (2) | JP5652984B2 (da) |
| AT (1) | ATE353954T1 (da) |
| AU (1) | AU2003269760B2 (da) |
| CY (1) | CY1106573T1 (da) |
| DE (1) | DE60218173T2 (da) |
| DK (1) | DK1408106T3 (da) |
| ES (1) | ES2282355T3 (da) |
| NZ (1) | NZ539843A (da) |
| PT (1) | PT1408106E (da) |
| WO (1) | WO2004032951A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2282355T3 (es) | 2002-10-11 | 2007-10-16 | Sentoclone Ab | Inmunoterapia de cancer. |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| US20050249699A1 (en) * | 2004-05-05 | 2005-11-10 | Stoff Jesse A | Immunodynamic complexes and methods for using and preparing such complexes |
| CA2619735C (en) * | 2005-08-31 | 2014-05-27 | Ith Immune Therapy Holdings Ab | Treatment of inflammatory bowel disease |
| RU2399382C2 (ru) * | 2005-12-21 | 2010-09-20 | Сентоклон Аб | Улучшенный способ увеличения числа опухоле-реактивных т-лимфоцитов в иммунотерапии онкологических больных |
| US8007785B2 (en) | 2005-12-21 | 2011-08-30 | Sentoclone International Ab | Method for treating colon cancer with tumour-reactive T-lymphocytes |
| EP1966370B1 (en) * | 2005-12-21 | 2013-02-20 | SentoClone International AB | Method for obtaining T-lymphocytes |
| WO2007071410A1 (en) * | 2005-12-21 | 2007-06-28 | Sentoclone Ab | Method for treating urinary bladder cancer |
| WO2007071390A1 (en) * | 2005-12-21 | 2007-06-28 | Sentoclone Ab | Method for treating malignant melanoma |
| US7951365B2 (en) * | 2007-06-27 | 2011-05-31 | Deifiera Falun Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types |
| EP2303319B1 (en) | 2008-06-20 | 2016-10-05 | Duke University | Compositions, methods and kits for eliciting an immune response |
| AU2009270434B2 (en) * | 2008-07-18 | 2015-04-09 | Sentoclone International Ab | Composition comprising in vitro expanded T-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer |
| CA2748931A1 (en) * | 2009-01-14 | 2010-07-22 | Health Research Inc. | Methods and compositions containing mtor inhibitors for enhancing immune responses |
| CN110878282A (zh) * | 2019-05-09 | 2020-03-13 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种肿瘤抗原特异性t淋巴细胞的制备方法 |
| CA3228697A1 (en) | 2021-08-30 | 2023-03-09 | Edward L. Perkins | Synthetic chromosome encoding two or more chimeric antigen receptors binding to tumor associated antigens |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311688A (en) * | 1979-10-29 | 1982-01-19 | Serono Laboratories Inc. | Composition and method for cancer detection in humans |
| WO1990005183A1 (en) * | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| JPH05502369A (ja) * | 1989-09-14 | 1993-04-28 | セルコ、インコーポレイテッド | 養子免疫療法に用いられる生体外増殖リンパ性細胞の製造方法 |
| US5814295A (en) | 1992-04-10 | 1998-09-29 | The Ohio State University Research Foundation | Determination of lymph nodes enriched in tumor reactive cells their proliferation and their use in adoptive cellular therapy |
| US20020182730A1 (en) * | 1995-07-26 | 2002-12-05 | Micheal L. Gruenberg | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
| WO1997046256A1 (en) * | 1996-05-23 | 1997-12-11 | The Scripps Research Institute | Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells |
| EP1071450A2 (en) | 1998-04-23 | 2001-01-31 | Arch Development Corporation | Combination of antigen pulsed apcs and interleukin 12 for tumour and viral therapy |
| AU4603499A (en) * | 1998-06-26 | 2000-01-17 | Joergen Agnholt | Methods of expanding and selecting disease associated t-cells |
| WO2001005433A2 (en) * | 1999-07-14 | 2001-01-25 | Board Of Regents, The University Of Texas System | Delivery and retention of activity agents to lymph nodes |
| GB0007088D0 (en) * | 2000-03-23 | 2000-05-17 | Torsana A S | Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates |
| US7012098B2 (en) * | 2001-03-23 | 2006-03-14 | Pharmacia Corporation | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers |
| US20030228635A1 (en) * | 2002-02-15 | 2003-12-11 | Renovar, Inc. | Cell proliferation assays and methods |
| US7718762B2 (en) | 2002-08-02 | 2010-05-18 | South Alabama Medical Science Foundation | Cancer vaccines containing epitopes of oncofetal antigen |
| EP1560924A4 (en) | 2002-08-16 | 2006-05-31 | Wayne John Cancer Inst | MOLECULAR LYMPHATIC MAPPING OF VIRCHOV LYMPHOTIC NODES |
| ES2282355T3 (es) | 2002-10-11 | 2007-10-16 | Sentoclone Ab | Inmunoterapia de cancer. |
| WO2004038029A1 (ja) * | 2002-10-24 | 2004-05-06 | Dnavec Research Inc. | T細胞に遺伝子を導入する方法 |
| EP1419787A1 (de) | 2002-11-18 | 2004-05-19 | Uwe Prof. Dr. Till | Lymphknoten-Kontrastmittel |
| RU2399382C2 (ru) * | 2005-12-21 | 2010-09-20 | Сентоклон Аб | Улучшенный способ увеличения числа опухоле-реактивных т-лимфоцитов в иммунотерапии онкологических больных |
| US8007785B2 (en) * | 2005-12-21 | 2011-08-30 | Sentoclone International Ab | Method for treating colon cancer with tumour-reactive T-lymphocytes |
| WO2007071410A1 (en) * | 2005-12-21 | 2007-06-28 | Sentoclone Ab | Method for treating urinary bladder cancer |
| WO2007071390A1 (en) * | 2005-12-21 | 2007-06-28 | Sentoclone Ab | Method for treating malignant melanoma |
| EP1966370B1 (en) * | 2005-12-21 | 2013-02-20 | SentoClone International AB | Method for obtaining T-lymphocytes |
| US7951365B2 (en) * | 2007-06-27 | 2011-05-31 | Deifiera Falun Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types |
| AU2009270434B2 (en) * | 2008-07-18 | 2015-04-09 | Sentoclone International Ab | Composition comprising in vitro expanded T-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer |
-
2002
- 2002-10-11 ES ES02022787T patent/ES2282355T3/es not_active Expired - Lifetime
- 2002-10-11 PT PT02022787T patent/PT1408106E/pt unknown
- 2002-10-11 DE DE60218173T patent/DE60218173T2/de not_active Expired - Lifetime
- 2002-10-11 EP EP07002830A patent/EP1808200A3/en not_active Ceased
- 2002-10-11 AT AT02022787T patent/ATE353954T1/de active
- 2002-10-11 EP EP02022787A patent/EP1408106B1/en not_active Expired - Lifetime
- 2002-10-11 DK DK02022787T patent/DK1408106T3/da active
-
2003
- 2003-10-08 NZ NZ539843A patent/NZ539843A/en not_active IP Right Cessation
- 2003-10-08 US US10/530,738 patent/US8709404B2/en active Active
- 2003-10-08 JP JP2004542956A patent/JP5652984B2/ja not_active Expired - Fee Related
- 2003-10-08 WO PCT/SE2003/001573 patent/WO2004032951A1/en active Application Filing
- 2003-10-08 AU AU2003269760A patent/AU2003269760B2/en not_active Ceased
-
2007
- 2007-05-10 CY CY20071100625T patent/CY1106573T1/el unknown
-
2012
- 2012-02-06 JP JP2012023236A patent/JP5946282B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012197260A (ja) | 2012-10-18 |
| JP5652984B2 (ja) | 2015-01-14 |
| JP5946282B2 (ja) | 2016-07-06 |
| JP2006507262A (ja) | 2006-03-02 |
| EP1808200A3 (en) | 2007-09-19 |
| DE60218173T2 (de) | 2007-11-22 |
| EP1408106A1 (en) | 2004-04-14 |
| EP1808200A2 (en) | 2007-07-18 |
| AU2003269760A1 (en) | 2004-05-04 |
| ES2282355T3 (es) | 2007-10-16 |
| DE60218173D1 (de) | 2007-03-29 |
| PT1408106E (pt) | 2007-04-30 |
| NZ539843A (en) | 2008-05-30 |
| AU2003269760B2 (en) | 2008-08-28 |
| ATE353954T1 (de) | 2007-03-15 |
| CY1106573T1 (el) | 2012-01-25 |
| US20070141026A1 (en) | 2007-06-21 |
| EP1408106B1 (en) | 2007-02-14 |
| US8709404B2 (en) | 2014-04-29 |
| WO2004032951A1 (en) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1408106T3 (da) | Cancer immunterapi | |
| de Bruin et al. | Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization | |
| Muthuswamy et al. | NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells | |
| Bhatia et al. | Intratumoral delivery of plasmid IL12 via electroporation leads to regression of injected and noninjected tumors in Merkel cell carcinoma | |
| Chaudhary et al. | Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs | |
| Owen et al. | Modelling the macrophage invasion of tumours: Effects on growth and composition | |
| Lally et al. | Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading | |
| May et al. | Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy | |
| US20090123443A1 (en) | Method for Treating Colon Cancer | |
| Festenstein | The biological consequences of altered MHC expression on tumours | |
| Yang et al. | Insights into local tumor microenvironment immune factors associated with regression of cutaneous melanoma metastases by Mycobacterium bovis Bacille Calmette–Guérin | |
| Kim et al. | Metastatic colon cancer cell populations contain more cancer stem‑like cells with a higher susceptibility to natural killer cell‑mediated lysis compared with primary colon cancer cells | |
| Tremante et al. | A melanoma immune response signature including Human Leukocyte Antigen‐E | |
| Delgado et al. | KIR receptor‐ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cells | |
| Berinstein et al. | Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen | |
| Page et al. | A phase Ib study of preoperative, locoregional IRX-2 cytokine immunotherapy to prime immune responses in patients with early-stage breast cancer | |
| Baba et al. | Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B | |
| Eggers | Autoradiographic and fluorescence antibody studies of the human host immune response to gliomas | |
| Oka et al. | Prostaglandin E2 levels and lymphocyte subsets in portal venous drainage of colorectal cancers | |
| Inozume | Adoptive cell transfer therapy for melanoma | |
| Mannweiler et al. | Colliding/concomitant tumors of the intestine: report of 3 cases | |
| Ikeda et al. | Multiple malignant melanoma and squamous-cell carcinoma in a burn scar | |
| Letsch et al. | Peptide vaccination after repeated resection of metastases can induce a prolonged relapse‐free interval in melanoma patients | |
| Russell et al. | USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics | |
| Tsuneyama et al. | Expression of MAGE‐A3 in intrahepatic cholangiocarcinoma and its precursor lesions |